Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898517 | 0.90 | HTR2A (0.46) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| SCHEMBL7697170 | 0.71 | DRD2 (0.53) | DRD2HTR2ADRD3SLC6A4ACHE | |
| SCHEMBL8809389 | 0.71 | DRD2 (0.39) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| SCHEMBL8917974 | 0.70 | DRD2 (0.38) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| Hydrochloric Acid SCHEMBL8920393 | 0.70 | CTSS (0.48) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| SCHEMBL8916164 | 0.70 | CTSS (0.48) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| Hydrochloric Acid SCHEMBL8918060 | 0.69 | CTSS (0.48) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| Hydrochloric Acid SCHEMBL8920342 | 0.69 | CTSS (0.49) | CTSSDRD2HTR2ADRD3SLC6A4 | |
| SCHEMBL8916650 | 0.69 | DRD2 (0.39) | DRD2HTR2ADRD3SLC6A4ACHE | |
| SCHEMBL8810725 | 0.69 | DRD2 (0.39) | CTSSDRD2HTR2ADRD3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806275-B2 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6407121-B1 | DOPAMINE D4 RECEPTOR ANTAGONISTS; PSYCHOLOGICAL AND BRAIN DISORDERS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1070715-A1 | ARYLPIPERIDINE DERIVATIVES AND USE THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | DRD1, DRD4, DRD2 | CTSS 3608/4885DRD2 3/4885HTR2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.